ClinicalTrials.gg
CompletedNCT01140906Updated Feb 11, 2014Results posted

Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

A Phase 3 interventional study of Placebo and Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-02-11.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
607
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
11th of 54
607 · median 413
Started
2010
with 5 others
Phase 3
31 of 54
1 open now
Registered
11th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 11th largest by enrollment, is one of 6 that started in 2010, is one of 31 in phase 3, and was the 11th registered.

Depressive Disorder, Major

3,047 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy, tolerability and the safety of two fixed doses of vortioxetine in the treatment of major depressive disorder.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major depressive disorder
  • Placebo-controlled
  • Active reference
  • Multicenter study
  • Randomised study
  • Acute treatment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has recurrent MDD as the primary diagnosis according to ™ criteria (classification code 296.3x)
  • The patient has a MADRS total score >=26
  • The patient has a CGI-S score >=4
  • The patient has had the current episode of MDE for >3 months

Exclusion criteria

Exclusion Criteria:

  • Any current anxiety psychiatric disorder as defined in the TR
  • Current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV TR
  • Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV TR
  • Use of any psychoactive medication 2 weeks prior to screening and during the study
  • The patient is at significant risk of suicide or has a score >=5 on Item 10 (suicidal thoughts) of the MADRS, or has attempted suicide within 6 months prior to the Screening Visit

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
607 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Vortioxetine: 15 mg

    Drug: Vortioxetine (Lu AA21004)

  • Experimental
    Vortioxetine: 20 mg

    Drug: Vortioxetine (Lu AA21004)

  • Other
    Duloxetine: 60 mg

    Active Reference

    Drug: Duloxetine

Interventions

  • DrugPlacebo

    capsules, daily, orally

  • encapsulated tablets, daily, orally

    Also known as: Brintellix

  • encapsulated capsules, daily, orally

    Also known as: Cymbalta®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)

    Time frame: Week 8

  2. Change in Clinical Status Using CGI-I Score at Week 8

    The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.

    Time frame: Week 8

  3. Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20

    Time frame: Baseline and Week 8

  4. Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)

    Time frame: Week 8

  5. Change From Baseline in SDS Total Score After 8 Weeks of Treatment

    The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.

    Time frame: Baseline and Week 8

  6. Change From Baseline in ASEX Total Score After 8 Weeks of Treatment

    The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient's recent sexual experience. Patients are asked to assess their own experience over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.

    Time frame: Baseline and Week 8

  7. Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine

    The Discontinuation-Emergent Signs and Symptoms Scale (DESS) was designed to evaluate possible effects of discontinuation of antidepressant therapy. It is a clinician-rated instrument that queries for signs and symptoms on a 43-item checklist (for example, agitation, insomnia, fatigue, and dizziness) to assess whether the item (event) is discontinuation-emergent. A new or worsened event reported after discontinuation of therapy scores 1 point on the checklist, and the DESS total score is the sum of all positive scores on the checklist. A higher score indicates more symptoms.

    Time frame: Change from Week 8 in DESS total score analyzed at Week 10

07

Results

Posted Feb 11, 2014

Participant flow

Patients were selected from psychiatric settings (private practices), outpatient clinics, and inpatient hospitals.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Started158151151147
Completed133117125131
Not completed25342616
Withdrew: Adverse event710177
Withdrew: Lack of efficacy6821
Withdrew: Non-compliance0101
Withdrew: Protocol violation5321
Withdrew: Withdrawal of consent6622
Withdrew: Lost to follow-up1102
Withdrew: Administrative or other reason0532

Outcome measures

PrimaryChange From Baseline in MADRS Total Score After 8 Weeks of Treatment.

The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.
units on a scalePlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.-11.70 ± 0.76-17.23 ± 0.79-18.79 ± 0.78-21.15 ± 0.77
Statistical analysis
  • Placebo vs Vortioxetine 15 mg · MMRM · p = <0.0001 (Since p-value \<0.025, hierarchically testing continued.) · Mean difference (final values): -5.53 · 95% CI -7.66 to -3.40To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Vortioxetine 20 mg · MMRM · p = <0.0001 (Since p-value \<0.025, hierarchically testing continued.) · Mean difference (final values): -7.09 · 95% CI -9.21 to -4.97To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Duloxetine 60 mg · MMRM · p = <0.0001 (This treatment arm was not in the testing sequence. A nominal p-value is provided.) · Mean difference (final values): -9.45 · 95% CI -11.55 to -7.35
SecondaryProportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
Time frame:
Week 8
Reported as:
Number · percentage of patients
Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
percentage of patientsPlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)32576274
Statistical analysis
  • Placebo vs Vortioxetine 15 mg · Adjusted Odds Ratio · p = <0.0001 (Wald's test. Since p-value \<0.025, hierarchically testing continued.) · Odds ratio (or): 2.80 · 95% CI 1.76 to 4.47To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Vortioxetine 20 mg · Adjusted Odds Ratio · p = <0.0001 (Wald's test. Since p-value \<0.025, hierarchically testing continued.) · Odds ratio (or): 3.36 · 95% CI 2.10 to 5.36To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Duloxetine 60 mg · Adjusted Odds Ratio · p = <0.0001 (This treatment arm was not in the testing sequence. A nominal p-value is provided.) · Odds ratio (or): 5.94 · 95% CI 3.61 to 9.78
SecondaryChange in Clinical Status Using CGI-I Score at Week 8

The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Change in Clinical Status Using CGI-I Score at Week 8
units on a scalePlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Change in Clinical Status Using CGI-I Score at Week 82.86 ± 0.092.18 ± 0.091.92 ± 0.091.75 ± 0.09
Statistical analysis
  • Placebo vs Vortioxetine 15 mg · MMRM · p = <0.0001 (Since p-value \<0.025, hierarchically testing continued.) · Mean difference (final values): -0.69 · 95% CI -0.94 to -0.44To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Vortioxetine 20 mg · MMRM · p = <0.0001 (Since p-value \<0.025, hierarchically testing continued.) · Mean difference (final values): -0.95 · 95% CI -1.20 to -0.70To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Duloxetine 60 mg · MMRM · p = <0.0001 (This treatment arm was not in the testing sequence. A nominal p-value is provided.) · Mean difference (final values): -1.12 · 95% CI -1.36 to -0.87
SecondaryChange From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20
Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20
units on a scalePlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20-12.20 ± 1.09-17.44 ± 1.08-18.62 ± 1.15-20.91 ± 1.10
Statistical analysis
  • Placebo vs Vortioxetine 15 mg · MMRM · p = 0.0007 (Since p-value \<0.025, hierarchically testing continued.) · Mean difference (final values): -5.24 · 95% CI -8.25 to -2.22To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Vortioxetine 20 mg · MMRM · p = <0.0001 (Since p-value \<0.025, hierarchically testing continued.) · Mean difference (final values): -6.42 · 95% CI -9.53 to -3.31To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Duloxetine 60 mg · MMRM · p = <0.0001 (This treatment arm was not in the testing sequence. A nominal p-value is provided.) · Mean difference (final values): -8.71 · 95% CI -11.73 to -5.69
SecondaryProportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
Time frame:
Week 8
Reported as:
Number · percentage of patients
Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
percentage of patientsPlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)19353854
Statistical analysis
  • Placebo vs Vortioxetine 15 mg · Adjusted Odds Ratio · p = 0.0016 (Wald's test. Since p-value \<0.025, hierarchically testing continued.) · Odds ratio (or): 2.32 · 95% CI 1.37 to 3.91To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Vortioxetine 20 mg · Adjusted Odds Ratio · p = 0.0002 (Wald's test. Since p-value \<0.025, hierarchically testing continued.) · Odds ratio (or): 2.65 · 95% CI 1.58 to 4.44To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Duloxetine 60 mg · Adjusted for Odds Ratio · p = <0.0001 (Wald's test. This treatment arm was not in the testing sequence. A nominal p-value is provided.) · Odds ratio (or): 5.01 · 95% CI 2.99 to 8.37
SecondaryChange From Baseline in SDS Total Score After 8 Weeks of Treatment

The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in SDS Total Score After 8 Weeks of Treatment
units on a scalePlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Change From Baseline in SDS Total Score After 8 Weeks of Treatment-4.46 ± 0.82-7.70 ± 0.89-8.38 ± 0.85-11.39 ± 0.85
Statistical analysis
  • Placebo vs Vortioxetine 15 mg · MMRM · p = 0.0054 (Since p-value \<0.025, hierarchically testing continued.) · Mean difference (final values): -3.24 · 95% CI -5.51 to -0.97To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Vortioxetine 20 mg · MMRM · p = 0.0005 (Since p-value \<0.025, hierarchically testing continued.) · Mean difference (final values): -3.92 · 95% CI -6.11 to -1.73To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.
  • Placebo vs Duloxetine 60 mg · MMRM · p = <0.0001 (This treatment arm was not in the testing sequence. A nominal p-value is provided.) · Mean difference (final values): -6.93 · 95% CI -9.16 to -4.70
SecondaryChange From Baseline in ASEX Total Score After 8 Weeks of Treatment

The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient's recent sexual experience. Patients are asked to assess their own experience over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in ASEX Total Score After 8 Weeks of Treatment
units on a scalePlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Change From Baseline in ASEX Total Score After 8 Weeks of Treatment0.28 ± 0.42-0.39 ± 0.43-0.20 ± 0.43-1.25 ± 0.42
Statistical analysis
  • Placebo vs Vortioxetine 15 mg · MMRM · p = 0.2524 (A nominal p-value is provided.) · Mean difference (final values): -0.67 · 95% CI -1.83 to 0.48No correction for multiplicity was made.
  • Placebo vs Vortioxetine 20 mg · MMRM · p = 0.4186 (A nominal p-value is provided.) · Mean difference (final values): -0.48 · 95% CI -1.64 to 0.68No correction for multiplicity was made.
SecondaryPotential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine

The Discontinuation-Emergent Signs and Symptoms Scale (DESS) was designed to evaluate possible effects of discontinuation of antidepressant therapy. It is a clinician-rated instrument that queries for signs and symptoms on a 43-item checklist (for example, agitation, insomnia, fatigue, and dizziness) to assess whether the item (event) is discontinuation-emergent. A new or worsened event reported after discontinuation of therapy scores 1 point on the checklist, and the DESS total score is the sum of all positive scores on the checklist. A higher score indicates more symptoms.

Time frame:
Change from Week 8 in DESS total score analyzed at Week 10
Reported as:
Mean · units on a scale
Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine
units on a scalePlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine0.15 ± 0.300.01 ± 0.310.72 ± 0.312.28 ± 0.30
Statistical analysis
  • Placebo vs Vortioxetine 15 mg · ANCOVA · p = 0.7372 (A nominal p-value is provided.) · Mean difference (final values): -0.14 · 95% CI -0.95 to 0.67
  • Placebo vs Vortioxetine 20 mg · ANCOVA · p = 0.1690 (A nominal p-value is provided.) · Mean difference (final values): 0.56 · 95% CI -0.24 to 1.37

Adverse events

Collected over Serious Adverse Events: 8-week double-blind treatment period and 4-week safety follow-up period Other Adverse Events: 8-week double-blind treatment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/158 (0%)44/158 (27.8%)
Vortioxetine 15 mg—0/151 (0%)61/151 (40.4%)
Vortioxetine 20 mg—2/151 (1.3%)70/151 (46.4%)
Duloxetine 60 mg—3/147 (2%)67/147 (45.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
Vaginal haemorrhageReproductive system and breast disorders0/1100/970/911/102
Intentional overdoseInjury, poisoning and procedural complications0/1580/1510/1511/147
Lumbar vertebral fractureInjury, poisoning and procedural complications0/1580/1510/1511/147
Self injurious behaviourPsychiatric disorders0/1580/1510/1511/147
Blood pressure decreasedInvestigations0/1580/1511/1510/147
DizzinessNervous system disorders0/1580/1511/1510/147
Intentional self-injuryPsychiatric disorders0/1580/1511/1510/147
Most frequent other events
Most frequent other events
EventPlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mg
NauseaGastrointestinal disorders16/15840/15148/15145/147
HeadacheNervous system disorders12/15816/15119/15116/147
DizzinessNervous system disorders10/1587/1517/15115/147
Dry mouthGastrointestinal disorders5/1585/1519/15114/147
HyperhidrosisSkin and subcutaneous tissue disorders6/1585/1510/15111/147
DiarrhoeaGastrointestinal disorders6/1586/15111/1519/147
FatigueGeneral disorders4/1586/1515/1518/147

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mgTotal
Mean48.1 ± 13.147.0 ± 14.646.2 ± 13.445.6 ± 13.646.7 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mgTotal
Female1109791102400
Male48546045207
MADRS baseline total score
MADRS baseline total score(units on a scale)PlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mgTotal
Mean31.5 ± 3.631.8 ± 3.431.2 ± 3.431.2 ± 3.531.4 ± 3.5
CGI-S baseline severity score
CGI-S baseline severity score(units on a scale)PlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mgTotal
Mean4.9 ± 0.74.9 ± 0.64.8 ± 0.74.8 ± 0.74.8 ± 0.7
HAM-A baseline total score
HAM-A baseline total score(units on a scale)PlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mgTotal
Mean20.8 ± 6.621.3 ± 6.820.4 ± 6.920.5 ± 6.720.8 ± 6.7
SDS total baseline score
SDS total baseline score(units on a scale)PlaceboVortioxetine 15 mgVortioxetine 20 mgDuloxetine 60 mgTotal
Mean19.8 ± 6.020.6 ± 5.320.7 ± 4.820.5 ± 4.420.4 ± 5.2
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Belzeaux R, Gorgievski V, Fiori LM, Lopez JP, Grenier J, Lin R, Nagy C, Ibrahim EC, Gascon E, Courtet P, Richard-Devantoy S, Berlim M, Chachamovich E, Theroux JF, Dumas S, Giros B, Rotzinger S, Soares CN, Foster JA, Mechawar N, Tall GG, Tzavara ET, Kennedy SH, Turecki G. GPR56/ADGRG1 is associated with response to antidepressant treatment. Nat Commun. 2020 Apr 2;11(1):1635. doi: 10.1038/s41467-020-15423-5. PubMed 32242018 ↗
  • Christensen MC, Florea I, Loft H, McIntyre RS. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Affect Disord. 2020 Feb 15;263:258-266. doi: 10.1016/j.jad.2019.11.074. Epub 2019 Nov 13. PubMed 31818787 ↗
  • Belzeaux R, Fiori LM, Lopez JP, Boucekine M, Boyer L, Blier P, Farzan F, Frey BN, Giacobbe P, Lam RW, Leri F, MacQueen GM, Milev R, Muller DJ, Parikh SV, Rotzinger S, Soares CN, Uher R, Foster JA, Kennedy SH, Turecki G. Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. J Clin Psychiatry. 2019 May 7;80(3):18m12556. doi: 10.4088/JCP.18m12556. PubMed 31087825 ↗
  • McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. J Clin Psychiatry. 2017 Jan;78(1):115-121. doi: 10.4088/JCP.16m10744. PubMed 27780334 ↗
  • Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014 May;29(3):138-49. doi: 10.1097/YIC.0000000000000018. PubMed 24257717 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010 and a primary completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2010
First posted
Jun 10, 2010
Start
May 2010
Primary completionActual
Sep 2011
Results first posted
Feb 11, 2014
Last update
Feb 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01140906
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jun 10, 2010
Start date
May 2010
Primary completion
Sep 2011
Results posted
Feb 11, 2014
Last update
Feb 11, 2014

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion